Date:10/17/2011

e guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our strategic plans and investments, new product launches and launch cadence, regulatory and provincial approvals in China, investments by the Chinese government, clinical trials, markets for our products and our market share of those markets in China, future revenues in China, product performance and acceptance, and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any i
'/>"/>

SOURCE Boston Scientific Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Boston Scientific Welcomes Introduction of Medical Device Regulatory Improvement Act in U.S. Senate
2. Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results
3. COPAN WASP® Lands at Prestigious Boston Medical Center
4. Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial
5. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent
6. Bluestar Silicones to Present Antimicrobial Silicones at Medical Silicones Conference in Boston
7. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
8. Boston Scientific Launches Coyote™ Balloon Catheter
9. Boston Scientific Sponsors New Patient Portal Dedicated to Pelvic Floor Disorders
10. Boston Scientific Names Michael F. Mahoney as Company President, Announces CEO Transition Plan
11. ConvaTec Announces Acquisition of Boston Medical Device